Specifically, they found that an IGF1/IGF1R inhibitor targeting YTHDF2-expressing cells could suppress GSC viability and the growth of glioblastoma in vivo in an m6A-dependent manner (70). This evidence concerns the gene YTHDF2 and glioblastoma.